Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
B Ricciuti, S Baglivo, A De Giglio… - … advances in respiratory …, 2018 - journals.sagepub.com
Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined
subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to …
subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to …
Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line–Indian consensus statement update (Under the aegis of Lung Cancer …
K Prabhash, A Vora, S Limaye, TP Sahoo… - Cancer Research …, 2021 - journals.lww.com
The management of patients with advanced non-small-cell lung cancer (NSCLC) is
becoming increasingly complex, with the identification of driver mutations/rearrangements …
becoming increasingly complex, with the identification of driver mutations/rearrangements …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - Translational Lung …, 2020 - ncbi.nlm.nih.gov
Background Brain metastasis is common in non-small cell lung cancer (NSCLC) and has an
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
even higher incidence in epidermal growth factor receptor (EGFR)-mutant cancers. Although …
Overcoming the acquired resistance to gefitinib in lung cancer brain metastasis in vitro and in vivo
In our previous work, PC-9-Br, a PC-9 brain seeking line established via a preclinical animal
model of lung cancer brain metastasis (LCBM), exhibited not only resistance to epidermal …
model of lung cancer brain metastasis (LCBM), exhibited not only resistance to epidermal …
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line–Indian consensus statement update
K Prabhash - South Asian journal of cancer, 2019 - thieme-connect.com
The management of advanced nonsmall cell lung cancer (NSCLC) patients is becoming
increasingly complex with the identification of driver mutations/rearrangements and …
increasingly complex with the identification of driver mutations/rearrangements and …
[HTML][HTML] The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations
L Decoster, P Giron, S Mignon… - … Lung Cancer Research, 2018 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S134-S137 tlcr. amegroups. com the Lancet Oncol by Wu et al., is a phase III …
(Suppl 2): S134-S137 tlcr. amegroups. com the Lancet Oncol by Wu et al., is a phase III …
Erlotinib: a targeted anticancer drug
Background: Over expression of epidermal growth factor receptor (EGFR) has been found to
play a vital role in cancer of lung and pancreas. Therapies that target EGFR-mediated …
play a vital role in cancer of lung and pancreas. Therapies that target EGFR-mediated …
肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的疗效及安全性研究.
陈宓， 贾霖， 韩建军， 贾利， 王允… - Progress in Modern …, 2016 - search.ebscohost.com
摘要目的: 研究肺癌脑转移患者应用靶向治疗联合放化疗同步治疗的临床疗效及安全性. 方法:
选取我院收治的肺癌脑转移患者74 例, 采取数字随机法分成观察组和对照组 …
选取我院收治的肺癌脑转移患者74 例, 采取数字随机法分成观察组和对照组 …
组蛋白的类泛素化修饰与发育调控研究进展.
裴培， 成翕悦， 王蕾， 林烨， 王珊… - Progress in Modern …, 2016 - search.ebscohost.com
泛素类泛素在真核生物体内广泛存在, 依赖泛素化及类泛素化蛋白的翻译后修饰已经被证实参与
很多细胞内的调控进程. 组蛋白是染色质的主要成分之一, 已经证实的组蛋白泛素类泛素翻译后 …
很多细胞内的调控进程. 组蛋白是染色质的主要成分之一, 已经证实的组蛋白泛素类泛素翻译后 …
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line.
K Prabhash - Indian Journal of Cancer, 2017 - search.ebscohost.com
The management of advanced nonsmall cell lung cancer (NSCLC) patients is becoming
complex with the identification of driver mutations and targeted therapies. The expert group …
complex with the identification of driver mutations and targeted therapies. The expert group …